Last updated: 11/03/2018 16:37:38

Prevalence-based health and economic model of the bivalent versus the quadrivalent human papillomavirus (HPV) vaccine

GSK study ID
114420
See study documents
Clinicaltrials.gov ID
NCT01702337
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Additional Health and Economic Impact of the bivalent versus the quadrivalent HPV vaccine in Taiwan: results of a prevalence-based model
Trial description: This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and the quadrivalent HPV vaccine (HPV-2).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Annual number of lesions prevented by each vaccine

Timeframe: Over a one-year period

Lesion related total cost averted by each vaccine

Timeframe: Over a one-year period

Additional costs averted by HPV-1 vaccine compared to HPV-2 vaccine

Timeframe: Over a one-year period

Secondary outcomes:
Not applicable
Interventions:
  • Other: Prevalence-based model
    • Enrollment:
    1
    Primary completion date:
    Not applicable
    Observational study model:
    Other
    Time perspective:
    Other
    Clinical publications:
    ADDITIONAL HEALTH AND ECONOMIC IMPACT OF THE BIVALENT VERSUS THE QUADRIVALENT HPV VACCINE IN TAIWAN: RESULTS OF A PREVALENCE-BASED MODEL, Ho. T.H., van Enckevort, P.J. & Demarteau, N. Poster presented at: ISPOR, 4th Asia-Pacific Conference, 5-7 September 2010, Phuket, Thailand.
    Medical condition
    Human Papillomavirus Infection
    Product
    SB580299
    Collaborators
    Not applicable
    Study date(s)
    February 2010 to February 2010
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female
    Age
    Not applicable+ years
    Accepts healthy volunteers
    Yes
    • Female subjects vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan (hypothetical group).
    • Not applicable.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Female subjects vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan (hypothetical group).
    Exclusion criteria:
    • Not applicable.

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2010-23-02

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website